Key clinical point: Response rates were high without dose limiting toxicities for propranolol added to pembrolizumab in treatment-naive metastatic melanoma, providing a basis for further study.

Major finding: Complete or partial responses were observed in 78% of patients with antitumor activity in all patients receiving 30 mg b.i.d.

Study details: The phase 1 study comprised nine patients receiving 10, 20, or 30 mg of propranolol b.i.d. added to 200 mg of pembrolizumab every 3 weeks.

Disclosures: The study was funded by Roswell Park, private, and NIH grants. The authors had no disclosures.